Holen Sie sich die Stockscreener-App
45.17
3.50%
-1.66
Handel nachbörslich:
45.19
0.02
+0.04%
Biohaven Ltd Aktie (BHVN) Neueste Nachrichten
Multiple System Atrophy Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma - The Globe and Mail
Psoriasis Market is expected to rise at a significant CAGR, DelveInsight | Hangzhou Highlightll Pharmaceutical Co., Ltd, Biohaven Pharmaceuticals, Inc., SFA Therapeutics, Bristol-Myers Squibb - Barchart
Biohaven Ltd. (NYSE:BHVN) Shares Sold by First Turn Management LLC - MarketBeat
Victory Capital Management Inc. Buys 145,960 Shares of Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Biohaven (NYSE:BHVN) Stock Price Down 8%Should You Sell? - MarketBeat
Janus Henderson Group PLC's Strategic Acquisition of Biohaven Lt - GuruFocus.com
Biohaven's (BHVN) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments - The Malaysian Reserve
Biohaven shares rise as TD Cowen lifts price target to $75 - Investing.com Australia
Royal Bank of Canada Issues Pessimistic Forecast for Biohaven (NYSE:BHVN) Stock Price - MarketBeat
12,400 Shares in Biohaven Ltd. (NYSE:BHVN) Acquired by SpiderRock Advisors LLC - MarketBeat
Trend Tracker for (BHVN) - Stock Traders Daily
Brokerages Set Biohaven Ltd. (NYSE:BHVN) Price Target at $61.92 - MarketBeat
Biohaven Stock Soars on Drug Trial Results: Time to Jump In? - MSN
Vanguard Group Inc's Strategic Acquisition in Biohaven Ltd - GuruFocus.com
(BHVN) Technical Data - Stock Traders Daily
Biohaven's (BHVN) "Overweight" Rating Reiterated at Cantor Fitzgerald - MarketBeat
Cadent Capital Advisors LLC Invests $1.77 Million in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
(BHVN) Trading Advice - Stock Traders Daily
Scholar Rock stock could benefit from Biohaven's Ph3 results, Truist raises potential rally outlook - Investing.com India
BofA sustains Buy rating on Biohaven shares, sees SMA trial upside By Investing.com - Investing.com South Africa
BofA sustains Buy rating on Biohaven shares, sees SMA trial upside - Investing.com UK
Analysts Set Biohaven Ltd. (NYSE:BHVN) Target Price at $61.92 - MarketBeat
Biohaven: A Complicated Tale (NYSE:BHVN) - Seeking Alpha
Biohaven Ltd. (NYSE:BHVN) Shares Acquired by AQR Capital Management LLC - MarketBeat
(BHVN) Investment Analysis - Stock Traders Daily
17,064 Shares in Biohaven Ltd. (NYSE:BHVN) Acquired by Squarepoint Ops LLC - MarketBeat
Biohaven retains Outperform stock rating on clinical results By Investing.com - Investing.com South Africa
Biohaven holds steady with $60 target on SMA trial optimism - Investing.com India
Biohaven holds steady with $60 target on SMA trial optimism By Investing.com - Investing.com Australia
Biohaven maintains Buy rating with $59 target amid SMA trial optimism By Investing.com - Investing.com South Africa
Biohaven (NYSE:BHVN) Stock Price Up 4.9%Here's What Happened - MarketBeat
Vladimir Coric Buys Handful Of Shares In Biohaven - Simply Wall St
Cantor Fitzgerald Reiterates "Overweight" Rating for Biohaven (NYSE:BHVN) - MarketBeat
Biohaven Stock Spikes After Drug Candidate To Treat Rare Neurodegenerative Disease Shows Promise - MSN
Analysts’ Recent Ratings Changes for Biohaven (BHVN) - Defense World
Biohaven (NYSE:BHVN) Price Target Raised to $68.00 at JPMorgan Chase & Co. - MarketBeat
Biohaven (NYSE:BHVN) Shares Gap Up After Insider Buying Activity - MarketBeat
John W. Childs Purchases 21,052 Shares of Biohaven Ltd. (NYSE:BHVN) Stock - Defense World
Bullish Biohaven Insiders Loaded Up On US$41.7m Of Stock - Yahoo Finance
Biohaven director Childs buys shares worth nearly $1 million By Investing.com - Investing.com South Africa
Biohaven CEO Vlad Coric acquires $999,970 in company stock By Investing.com - Investing.com Australia
Biohaven director Childs buys shares worth nearly $1 million - Investing.com
Biohaven CEO Vlad Coric acquires $999,970 in company stock - Investing.com India
Marshall Wace LLP Sells 677,724 Shares of Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares - Lelezard.com
Biohaven Ltd. (NYSE:BHVN) Shares Sold by Point72 Asset Management L.P. - MarketBeat
Biohaven sets public offering price at $47.50 per share By Investing.com - Investing.com Australia
Biohaven shares could see growth as MDD and bipolar studies advance, per TD Cowen - Investing.com India
Biohaven (NYSE:BHVN) Sees Strong Trading Volume - MarketBeat
Biohaven sets public offering price at $47.50 per share - Investing.com
Biohaven down after $250 mln stock offering prices - XM
Biohaven Announces Pricing of $250 Million Public Offering of Common Shares - Nasdaq
Biohaven launches $250 million public stock offering By Investing.com - Investing.com Australia
After-hours movers: IGM Biosciences, Biohaven Pharma, Acadia Realty Trust By Investing.com - Investing.com South Africa
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):